Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, June 20, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT), Allergan, Inc. (NYSE: AGN) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3940-100free.
Valeant Pharmaceuticals Intl Inc Analyst Notes
On June 16, 2014, Valeant Pharmaceuticals Intl Inc (Valeant) announced that its Restylane® Silk Injectable Gel with 0.3% Lidocaine has received marketing clearance from the U.S. Food and Drug Administration (FDA). According to the Company, Restylane® Silk Injectable Gel is indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. J. Michael Pearson, Chairman and CEO remarked, "We are pleased to have received marketing clearance from the FDA for Restylane® Silk so quickly after the approval of Jublia. Our R&D team is hitting on all cylinders and demonstrating that Valeant has a successful, output-focused R&D model that concentrates on areas of expertise where we are confident that our investments will pay off." The full analyst notes on Valeant are available to download free of charge at:
Pfizer Inc. Analyst Notes
On June 17, 2014, Pfizer Inc. (Pfizer) announced that a Biologics License Application (BLA) has been submitted to the U.S. Food and Drug Administration (FDA) for bivalent recombinant LP2086 (rLP2086), which is the Company's vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. Commenting on the submission, Dr. Emilio Emini, Senior Vice President of Vaccine Research and Development for Pfizer said, "The BLA submission for bivalent rLP2086 marks an important step toward our goal of helping to protect adolescents and young adults against this difficult to diagnose and often deadly disease. There is an urgent public health need to help prevent meningococcal B disease through vaccination, and we will continue to work closely with the FDA in our efforts to advance our vaccine candidate." The full analyst notes on Pfizer are available to download free of charge at:
Actavis plc Analyst Notes
On June 17, 2014, Actavis plc (Actavis) and Forest Laboratories, Inc. announced that all proposals related to Actavis' planned acquisition of Forest Laboratories, Inc (Forest) were approved by shareholders of both companies at shareholder meetings held on the date of announcement. Actavis said that both companies'shareholder approvals satisfy certain conditions to the closing of the transaction, which is expected to occur mid-year, subject to certain regulatory approvals and other customary closing conditions. The full analyst notes on Actavis are available to download free of charge at:
Allergan, Inc. Analyst Notes
On June 16, 2014, Allergan, Inc. (Allergan) repeated its concerns in relation to Valeant Pharmaceuticals International, Inc.'s (Valeant) unsustainable business model, which depends on serial acquisitions and cost reductions, as compared to top-line revenue growth and operational excellence. Allergan also stated that a number of third parties have also expressed similar views. The Company added that as previously announced, its Board of Directors had determined that the re-revised unsolicited proposal dated May 30, 2014 by Pershing Square Capital Management, L.P. and Valeant substantially undervalues the Company, creating significant risks and uncertainties for the stockholders of Allergan, and is not in the best interests of the Company and its stockholders. The full analyst notes on Allergan are available to download free of charge at:
Teva Pharmaceutical Industries Ltd Analyst Notes
On June 17, 2014, Teva Pharmaceutical Industries Ltd (Teva) announced that it has reached settlements with Actavis, Lupin and Apotex regarding U.S. Patent 7,132,570 (the 570 patent) for its wakefulness product, NUVIGIL® (armodafinil) tablets. The Company informed that these settlements dismiss a pending appeal with the United States Court of Appeals for the Federal Circuit of a trial court decision that found the '570 patent to be valid and infringed. The Company stated that under the settlement, it has granted licenses to allow these parties to market their generic products 180 days after Mylan, the first generic company to file an abbreviated new drug application for the 50 mg, 150 mg, and 250 mg dosages of NUVIGIL®. The settlements also permit Actavis to launch generic 100 mg and 200 mg dosages in June 2016, and the others may launch these dosages 180 days after Actavis. The full analyst notes on Teva are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.